The types of treatments and interventions being developed for chronic neurodegenerative disorders have expanded considerably in recent years. In addition to the variety of targets being pursued, strategies have moved from symptom management to more directed disease-modifying approaches. Among them are antibody-based therapies, which are not only being evaluated for a range of tauopathies and synucleinopathies, but are also emerging as a potential application for monogenic disorders of the central nervous system (CNS), including Huntington's disease (HD) . Despite the excitement around the early trial data of anti-sense oligonucleotides (ASO) treatment for such disorders, antibody therapies may hold the key to tackling another aspect of the disease that could be critical to its pathogenesis. While gene-based methodologies are designed to lower, predominantly within cellular elements, mutant huntingtin protein (mHtt) -the genetic product of HD -the pathological protein is abundant in free forms and in several compartments including the cerebrospinal fluid, the plasma and the extracellular matrix. With accumulating evidence for the spreading and seeding capacities of mHtt, it may indeed be essential to target the protein both intracellularly and extracellularly. Therefore, free forms of mHtt not only represents an ideal target for antibodies, but one that needs to be addressed if meaningful and maximal clinical benefits are to be expected. This review explores the potential use of antibody-based therapies to treat HD, including the rationale for this approach as well as the pre-clinical data supporting it. The potential challenges that will need to be considered if such route is to be pursued clinically are also discussed.
What is the rational for developing antibody-based therapies in HD
Huntington's disease (HD) is a neurodegenerative disorder that progresses to death over 10 to 30 years from clinical onset (Tang and Feigin, 2012) . During the premanifest phase, subtle changes in personality, cognition and motor control can be observed which lead to the diagnosis of manifest HD, essentially based on motor abnormalities. The main neuropathological features of HD relate to major cell loss in the striatum as well as a host of other brain structures, in particular the cerebral cortex (Reiner et al., 2011; Vonsattel, 2008) . However, HD is not just a disease of the central nervous system (CNS) . A number of periphery-associated features have been described including muscle wasting (Zielonka et al., 2014) , cardiac problems (Bär et al., 2008) and pancreatic dysfunction leading to changes in glucose homeostasis (Stüwe et al., 2013) .
HD displays an autosomal dominant pattern of inheritance and is caused by a pathological CAG repeat expansion exceeding 35 in exon 1 of the huntingtin gene, which encodes for huntingtin (Htt), a cytoplasmic protein ubiquitously expressed in all cells of the body (Venkatraman et al., 2004) . This CAG expansion leads to the production of the mutant huntingtin protein (mHtt), which is characterized by an expanded polyglutamine (polyQ) stretch (Jana et al., 2001; Davies et al., 1997) . While driving pathology within cells, mHtt is also found extracellularly in the cerebrospinal fluid (CSF), plasma and extracellular matrix (Jeon et al., 2016; Wild et al., 2015; Cicchetti et al., 2014; Liu et al., 2007; Gutekunst et al., 1999) . This extracellular pool of mHtt has not been given much consideration in terms of its role in the disease process but there is now growing evidence challenging this view. For example: 1) the peripheral mHtt load seemingly influences CNS-related features of the disease, at least from the perspective of the immune system; 2) mHtt can propagate and seed pathology and, although still largely speculative, 3) the prion-like behaviour of mHtt could be influencing clinical profiles, as elaborated in Braak's theory for Parkinson's disease (PD) . As such, extracellular mHtt represents a very attractive target given its tractability for therapeutic development and one that has been rather overlooked in the development of novel therapeutic approaches.
The interplay between peripheral mHtt load and CNS disorder
Changes in protein metabolism in skeletal muscles (Saudou and Humbert, 2016; Zheng and Diamond, 2012; Sassone et al., 2009; Bates, 2003) , reduction in hepatic mitochondrial function (Stüwe et al., 2013) and loss of lower limb strength (Caviston and Holzbaur, 2009 ) are commonly reported in premanifest HD carriers and a number of these abnormalities correlate with disease severity, including cognitive deficits and striatal atrophy. There is also accumulating evidence that early changes within the peripheral immune system may critically contribute to CNS-associated pathology (Bence et al., 2001; Steffan et al., 2000; Huang et al., 1998; Scherzinger et al., 1997; Smith, 1985) . For example, the presence of mHtt in peripheral monocytes has been reported to correlate with disease stage and progression of caudate atrophy in patients (Weiss et al., 2012) . In fact, alterations in components of the immune system (e.g. peripheral cytokine levels) have been detected as early as 16 years prior to the predicted onset of clinical symptoms (Björkqvist et al., 2008) . In pre-clinical models, genetic deletion of the cannabinoid receptor 2 (CB2), an immunomodulatory receptor mainly expressed in human tissue (Turcotte et al., 2016) , in a slow progressing model of HD (CB2-/-bred with BACHD) leads to accelerated motor deficits. In contrast, treatment with CB2 agonists extends the lifespan of these mice, along with a retardation in motor impairments, reduction in synapse loss and CNS inflammation (Bouchard et al., 2012) . Bone marrow transplantation has also been reported to confer some improvement on behavioural deficits in two mouse models of HD (YAC128 and BACHD) (Kwan et al., 2012b) , implying that deletion of peripheral cells loaded with mHtt can ameliorate central pathology.
The spreading and seeding properties of mHtt also confers toxicity
The toxicity of mHtt has long been established but in recent years, a possible new mechanism has begun to emerge; the concept that mHtt can propagate between cells and template pathology in a prion-like fashion. This theory builds, in part, on our observations that mHtt aggregates can be found within fetal striatal transplants in HD patients years after they were grafted (Cicchetti et al., 2014) . More recently, we have shown that fibroblasts or induced pluripotent stem cells (iPSCs) derived from HD patients injected into the ventricular system result in both motor and cognitive impairments in wild type (WT) mice. Postmortem analysis revealed that transplanted cells -which died shortly after injection possibly due to an immune response of the mouse against the human cells -released the protein aggregates into the host brain, provoking the loss of striatal medium spiny neurons in which mHtt aggregates were identified. This was further accompanied by an increased gliosis in associated brain regions, recapitulating several neuropathological aspects of the disease (Jeon et al., 2016) . We have additionally shown that exogenously administered mHtt can be taken up by a number of cell types in vitro, with measurable toxic consequences (Masnata et al., 2019) . WT mice injected with fibrillar form of Htt exon 1 protein fragments with a 48-glutamine repeat (Httex1-Q48) unilaterally within the cortex developed cognitive deficits, while similar injections into the lateral ventricles of newborn R6/2 transgenic HD mice precipitated both the motor and cognitive phenotypes characteristic of these animals. Another salient finding from this work was the presence of fibrillar mHtt in structures remote from the injection site, suggesting the spreading of mHtt. The capacity of mHtt to spread between cells implies that mHtt it is not always found inside cellular compartments, but is often present outside the cell boundary, as is obvious in post-mortem histological stainings of patients with HD (Cicchetti et al., 2014; Gutekunst et al., 1999) .
The prionic capacities of mHtt may influence clinical profiles
Clinically, manifestation of HD in patients with an identical CAG repeat length can develop disease at different ages and follow different clinical courses for reasons that are not altogether apparent (Gusella et al., 1983) . Gene modifiers, allelic variations, environmental factors as well as complex gene-environment interactions have all been suggested to contribute to the discrepancies in age of onset and disease severity. Genome-wide association (GWA) analyses conducted by the Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium have identified three loci that can slow or accelerate pathology (GeM-HD Consortium, 2015) . The phenomenon, although rare, whereby certain individuals have two mutant alleles, reveals that homozygous patients present with a more severe clinical course which includes an accelerated decline in motor and cognitive function (Squitieri et al., 2003) . Studies on large cohorts of Venezuelan HD kindreds have suggested that the variability in age of onset could be predominantly attributed to environmental factors, although they were not specifically identified (Wexler et al., 2004) . Aside from these factors, heterogeneity could also relate to the prionic capacity of mHtt, as has been suggested for synucleopathies (Melki, 2015; Peelaerts et al., 2015; Prusiner et al., 2015) . The seeding capacity of mHtt has now been shown along with neuronal toxicity in several cell models (Wagner et al., 2018; Masnata and Cicchetti, 2017) as well as in vivo paradigms (i.e. mouse, drosophila and C. elegans) Ko et al., 2018; Kim et al., 2017; Jeon et al., 2016; Babcock and Ganetzky, 2015) . In the HD drosophila model, it was explicitly demonstrated, using a fluorescence resonance energy transfer (FRET)-based aggregate seeding assay, that the smaller Httex1-Q97 aggregates were seeding competent . One of the strongest arguments in favour of a role for protein spread/seeding contributing to the expression of various clinical profiles is based on the work of Braak (Braak et al., 2003; Braak and Braak, 2000) . Observations in post-mortem tissue of PD patients have led to the hypothesis that alpha-synuclein (α-Syn) aggregates can spread from neuron to neuron starting from regions such as the olfactory bulb and/or the enteric nervous system (Rietdijk et al., 2017; Chu and Kordower, 2010; Li et al., 2008) , disseminating disease. This theory is in part supported by clinical evidence of anosmia (Doty, 2012) and gastrointestinal problems such as dysphagia, nausea and constipation experienced by patients years before the clinical diagnosis (Cersosimo and Benarroch, 2012; Pfeiffer, 2011) . As for PD, the prion-like capacities of mHtt could play a role in disease onset/severity, contributing to the large degree of clinical heterogeneity observed in patients with the same CAG repeat length.
There are currently no disease-modifying treatments available for HD and symptom management remains suboptimal, or altogether nonexistent for some aspects of the disease such as cognitive deficits. As of today, a number of important characteristics of the disease have been largely overlooked and it is therefore imperative they be considered in the development of novel therapeutic strategies. Along these lines, immuno-based therapeutics represent a novel and promising class of medications. These antibody-based approaches can be broadly grouped into one of the following categories: a) anti-mHtt antibodies, b) anti-tau antibodies (INT41, (Amaro and Henderson, 2016) ), c) anti-inflammatory antibodies (anti-semaphorin 4D, VX15/2503-N-131 by Vaccinex), and d) brain-derived neurotrophic factor (BDNF) mimetics (laquinimod: LEGATO-HD by TEVA or LM22A-4 as a BDNF agonist) (see review; Denis et al., 2019) . For the purpose of this review, we will concentrate on work related to anti-Htt/mHtt antibodies.
The current status of antibody-based therapy to treat HD
Designing novel immunotherapeutics for HD can be expected to be H.L. Denis, et al. Neurobiology of Disease 132 (2019) 104569 Table 1 Outcome of antibody-based therapies in pre-clinical models of HD -targeting intracellular mHtt. much more effective than what has been created thus far given our increasing knowledge of the Htt protein structure. Despite the fact that the structure of exon 1 coded segment of the protein -the fragment of Htt harbouring the disease-causing mutation -is still being elucidated, the polyQ region (amino acid (aa) 18 to 38), as well as other flanking domains within exon 1 such as the N-terminus (aa1-17 or aa1-20) and polyproline (polyP)/proline rich region (PRR) (aa39-78), have all been identified to influence the toxicity of mHtt (Duennwald et al., 2006) . By virtue of being present both within and outside cell compartments, mHtt can therefore be targeted using antibodies which would help diminish its production within cells, and, simultaneously, prevent the spreading of the pathological protein to other cells.
Targeting intracellular mHtt
Intrabodies targeting intracellular mHtt were developed in the late 1990s McCafferty et al., 1990; Huston et al., 1988) and have consequently been the most studied (Table 1 ). In early 2000s, and with the establishment of a large naive human spleen singlechain variable fragment (scFv) phage-display library (Marks et al., 1991) , the first intrabody for HD was made available (Lecerf et al., 2001) . Designed as a gene-based approach where recombinant antibodies, generally the antigen-binding fragment, are expressed in different intracellular compartments in order to interfere with the mutant proteins, intrabodies are smaller, simpler versions of antibodies. The genetic information is delivered to cells through a viral vector, predominantly adeno-associated viruses (AAV), which then manufactures functional antibodies to target specific proteins. The general mode of action of intrabodies is to either (i) neutralize the target protein by directly binding to its functional domain; (ii) interfere with the ability of the pathological proteins to interact with other critical proteins (i.e. binding partners); or (iii) redirect the pathogenic protein to a different subcellular compartment, for example the proteasome for degradation (Cardinale and Biocca, 2008) . Intrabodies targeting the following protein domains of the soluble form of Htt/mHtt have been tested for: 1) the polyQ domain; 2) the polyP domain; 3) the N-terminal exon 1 domain as well as 4) for mHtt aggregates themselves (Table 1, Fig. 1 ).
Targeting the polyQ domain
MW1 and MW2 scFv intrabodies raised against the expanded polyQ tract of the soluble form of mHtt were among the first intrabodies designed to interfere with the aggregation mechanism. When tested in HEK293 cells, however, they accelerated aggregate formation and precipitated cell death (Khoshnan et al., 2002) for reasons that initially seemed obscure (Perutz, 1995) . However, this region is also known for its multiple interactions with other cellular proteins, which, if targeted, could provoke deleterious effects on the cells (Khoshnan et al., 2002) . The length of the polyQ stretch has also been implicated in the degradation of mHtt (Sherman and Goldberg, 2001 ) and accordingly, it was understood that intrabodies targeting the polyQ domain could counterproductively stabilize the mHtt conformation, thereby increasing its aggregation capacity/toxicity.
Targeting the polyP domain
MW7 -an scFv intrabody directed against the polyP tract of the soluble form of Htt/mHtt -has been shown to decrease mHtt aggregate formation, increase mHtt turnover with a consequent increase of cell survival, as observed in HEK293 cells (Butler et al., 2012; Southwell et al., 2008; Khoshnan et al., 2002) . However, the non-specific target engagement of the MW7 antibody, i.e. its ability to bind other polyP containing proteins, not just Htt/mHtt (Southwell et al., 2008) , prompted the development of more specific PRR binding intrabody clones. These antibodies, designated Happ 1 and Happ 3, were tested in vitro in HEK cells resulting in a dose-dependent beneficial effect on mHtt aggregation by reducing the soluble form of mHtt (Southwell et al., 2009 (Southwell et al., , 2008 . These changes were accompanied by an increased turnover of mHtt upon administration of either Happ 1 or 3 intrabodies in rat immortalized striatal neuronal cultures (ST14A) transfected with Httex1-Q97. Co-transfection of Happ 1 and Htt exon 1 (Httex1) in an ex vivo rat brain slice preparation showed that the number of surviving medium spiny neurons was also similar to control conditions (Southwell et al., 2008) . Happ 1 was further tested in five rodent models of HD (R6/2, N171-82Q, YAC128, BACHD and lentiviral model of HD (Httex1-Q103)) where it reduced the number of mHtt aggregates in both the cytoplasm and nucleus of striatal neurons and improved motor and cognitive deficits (rotarod, beam crossing, climbing, Abbreviations: AAV, adeno-associated virus; BHK-21, fibroblast derived from hamster kidney; COS-7, fibroblast derived from monkey kidney; HEK293, Human embryonic kidney 293 cells; Httex1-Qn, huntingtin exon 1 with 'n' glutamine repeats; mHtt, mutant huntingtin; PC12, pheochromocytoma of the rat adrenal medulla; PEST, peptide sequence that is rich in proline (P), glutamic acid (E), serine (S), and threonine (T) used as a signal peptide for protein degradation; ST14A, rat immortalized striatal neuronal cultures; scFv, single-chain variable fragment intrabody; rAAV, recombinant adeno-associated virus; WT, wild type. clasping, open-field and novel object recognition) (Southwell et al., 2009 ). However, despite these positive outcomes, solubility within the cytoplasm has been reported to be very low (< 10%) (Amaro and Henderson, 2016) . This led to the development of a panel of alternative intrabodies of which, an antibody labelled INT41 with the same specificity as Happ 1, was generated (Amaro and Henderson, 2016) . Flow cytometry analysis revealed that HEK cells expressing the Httex1-Q103-GFP exposed to Happ 1 or INT41 depicted significantly less mHtt aggregates in either case (Amaro and Henderson, 2016) . Using PC12 cell lines transfected with inducible full-length human Htt genes (Q23 or Q73), this intrabody was shown to be produced in the nucleus and cytoplasm, lowering soluble forms of Htt/mHtt in both of these cell compartments (Amaro and Henderson, 2016) . INT41 administration to 5-week old R6/2 mice delayed the onset of cognitive deficits in the Twater maze and post-mortem analyses revealed the presence of antibodies in the putamen, caudate and thalamic regions with a significant decrease in the size of aggregates in the striatum, where it was measured (Amaro and Henderson, 2016) . These findings have resulted in INT41 (VYBION Inc.) obtaining the status of orphan drug, bringing it closer to clinical trials in HD. VYBION Inc. is also testing the therapeutic potential of INT41 in other polyQ diseases, including spinobulbar muscular atrophy, three types of spinocerebellar ataxia as well as in AD (VYBION, 2018) . Indeed, INT41, which recognizes PRR/polyP regions on mHtt, will be used to target tau, also a PRR/polyP containing protein. INT41's ability to potentially reduce mHtt and tau simultaneously further lends support for its use in HD given that the pathology also includes signs of tauopathies (Cisbani et al., 2017; Gratuze et al., 2016; Vuono et al., 2015) . However, as with intrabodies targeting the polyQ domain, some caution must be exercised when targeting the polyP region of mHtt (Khoshnan et al., 2002) . Some of these intrabodies, in particular MW1, 2 and 7, can bind to other polyQ and polyP containing proteins and consequently, have an impact on cell survival in unaffected populations of neurons and glia.
Targeting the N-terminal exon 1 domain
The very first intrabody developed for HD was an antibody against the 17aa N terminal exon 1 domain of the soluble form of Htt/mHtt, designated scFv-C4. It was shown to inhibit aggregate formation and thereby reduce toxicity in Cos-7 cells (Lecerf et al., 2001) . Treatment with the 17aa intrabody has also been demonstrated to significantly increase the lifespan of a drosophila HD model (Wolfgang et al., 2005) , with an underlying decrease in the formation of Httex1-Q93 aggregates. The study also reported slower degeneration, as assessed by counting the number of healthy eye subunits (ommatidia) in the HD flies. Additionally, scFv-C4 was tested in the R6/1 mouse model where it was delivered into the striatum at different time points corresponding to a pre-degeneration phase or when neurodegeneration had begun (Snyder-Keller et al., 2010) . The results revealed that administration of scFv-C4 at the pre-onset stage had the most dramatic effects. The number of surviving cells without nuclear aggregates was significantly higher and the accumulation of aggregated mHtt was delayed. To eliminate the pathological protein, the scFv-C4 intrabody was fused to a proteosomal signal peptide (PEST) to direct the protein into the proteasome system for degradation (Butler and Messer, 2011) . Results indicated a reduction of Httex1-Q72 by 80-90%, when compared to scFv-C4 alone in ST14A cells.
In contrast, the reported effects of the study trialing the 20aa region of the soluble form of Htt/mHtt targeting intrabody were less positive. V L 12.3 was administered in vivo in five rodent models: a lentiviralgenerated HD model (Httex1-Q103) as well as 4 transgenic mouse models (YAC128, N171-82Q, BACHD and R6/2) (Southwell et al., 2009) . While V L 12.3 treatment improved behaviour and neuropathology in the lentiviral HD model, it had no effect in the YAC128 and in fact, led to worsening motor performance and shortened life span in the R6/2 mouse model (Southwell et al., 2009 ). This result emphasized the fact that the same therapeutic tested in one model does not necessarily have the same effects in another model, even if the treatment is given at a similar disease stage. These drastic differences in outcomes could be due to the fundamental differences in the way the genetic models are created as well as their respective genetic backgrounds. While the lentiviral-mediated mHtt model targets striatal cells that lead to motor deficits (de Almeida et al., 2002; Régulier et al., 2003) , the genetic mouse models display significant behavioural phenotypes with no or very little striatal neuronal loss. Taken together, the choice of potential epitopes to target mHtt is crucial, a fact demonstrated by the varying outcomes of the two types of antibodies constructed to recognize the first 17 or 20 aa.
Targeting mHtt aggregates
In addition to targeting soluble forms of mHtt, another possible approach would be to target the protein aggregates themselves. Accordingly, more recent developments have included generating an intrabody (referred to as W20) which specifically targets aggregated proteins. W20 is a conformation-dependent, pan-amyloid oligomer specific antibody recognizing amyloid oligomers encountered with mHtt, α-Syn and amyloid beta (Aβ), among others (Zha et al., 2016) . BACHD mice treated with W20 have shown a reduction of all forms of mHtt (soluble, insoluble, oligomeric and aggregated), which was accompanied by a decrease of neuroinflammation leading to improvements of motor and memory impairments. However, caution must be exercised when using conformational intrabodies as well, as demonstrated by studies using scFv-6E, another conformation-specific intrabody. This intrabody recognizes isomorphic fibrillar forms of mHtt and has been reported, when expressed in ST14A cells, to induce aggregation and oxidative stress leading to cell death (Kvam et al., 2009 ). The different outcomes of these two antibodies could be due to the fact that W20 binds to more stable oligomers, while scFv-6E recognizes fibrillar proteins that can still undergo conformational changes. On the other hand, aggregates may reflect a broader coping response triggered by misfolded mHtt. Observation of cells, collected over several days, have suggested that diffuse forms of mHtt predict neuronal cell death, but that the formation of aggregates reduce the levels of diffuse mHtt and striatal-associated neuronal death (Arrasate and Finkbeiner, 2012; Miller et al., 2010; Finkbeiner et al., 2006; Arrasate et al., 2004) . Mice expressing exons 1 (harbouring 120 glutamines) and 2 of the human Htt gene have aggregates but present no signs of neuronal dysfunction nor neurodegeneration (Slow et al., 2005) . Further investigations are warranted to determine whether targeting the aggregated form of mHtt is truly relevant to the pathology. Thus, important factors to consider when designing/choosing an intrabody for the treatment of HD include a) careful selection of the epitope (i.e. aa1-20 vs. aa1-17) or b) protein form (i.e. oligomers vs. fibrils) and c) rigorous testing in a number of animal models with possible comparisons with other intrabodies targeting the same, or similar epitopes.
Targeting extracellular mHtt
Targeting free/extracellular mHtt is an aspect of disease that has not been addressed by other therapeutic strategies currently being developed (e.g. gene silencing, anti-sense oligonucleotide (ASO)). The comparative ease of accessing extracellular pathogenic proteins by conventional antibodies, without the need for engineering and delivering more challenging intracellular versions of antibodies, makes it a very attractive target (Table 2 ). An additional beneficial attribute for targeting extracellular mHtt is the fact that this form of the protein is more prone to spread. Targeting free/extracellular mHtt could, accordingly, be conducted by passive and/or active immunization. Active immunization refers to the process of exposing the immune system to an exogenous substance -an antigen, mHtt in this case -to elicit an adaptive immune response. This process has the advantage of generating an acquired active immune response leading to the production of anti-Htt/mHtt antibodies, as long-term and possibly lifelong protection. On the other hand, passive immunization directly introduces pre-made antibodies into the body to protect individuals against a pathogenic antigen, such as mHtt. The injection of pre-made antibodies has the advantage of providing immediate protection. However, benefits are restricted to a short period of time; weeks to a few months depending on the stability of the antibody. Thus, passive immunization requires multiple injections to maintain its therapeutic effect. Both approaches offer advantages and disadvantages and have been considered for treating HD.
Active immunization
Active immunization against Htt/mHtt was initially reported in R6/ 2 mice (Miller et al., 2003) . The study employed plasmids to express an antigenic part of mHtt as an immunization approach. Plasmids encoding an mHtt N-terminal fragment (17aa + 103 glutamine residues, Httex1-Q103) were administered to R6/2 mice prompting the expression of the Httex1-Q103 fragments, which in turn stimulated an antigen-specific immune response against this mHtt fragment in vaccinated mice. R6/2 mice that efficiently produced anti-Httex1-Q103 antibodies (immunoresponsive) did not develop a diabetic phenotype, a well-known characteristic of this HD model. Although there were no differences between control and vaccinated mice with respect to the number of mHtt aggregates in pancreatic islet cells, vaccinated animals had enhanced insulin staining compared to controls, in line with improved glucose tolerance among immunoresponsive animals (Miller et al., 2003) . A more recent study tested an active immunization approach using peptide, protein and DNA plasmid immunization protocols in two transgenic HD mouse models (R6/1 and zQ175) (Ramsingh et al., 2015) . The strongest and most uniform production of antibodies against Httex1 was recorded when mice were injected with three nonoverlapping Httex1 coded peptides (aa1-17, aa49-60, aa74-88), conjugated with keyhole limpet hemocyanin to stimulate the immune system for polyclonal antibody production. No efficacy study was performed, leaving the functional benefits of these peptides undetermined. However, this trial highlighted a number of critical safety issues, as this type of vaccination was associated with a transcriptional dysregulation of immune genes, affecting cells involved in both innate and adaptive immune responses as well as increasing the expression of proinflammatory genes following immunization (Ramsingh et al., 2015) .
Using a protein immunization approach, we have recently reported that the injection of fibrillar Htt/mHtt in WT mice induced a robust antibody production. The length of the polyQ repeat was directly linked to the magnitude of the resulting immune response (Masnata et al., 2019) . The elicited immune response did not adversely affect the mice, supporting the safety and tolerability of such approach. However, their safety, efficacy and applicability to human subjects remain to be determined.
Passive immunization
Preformed antibodies specific to one epitope (monoclonal) or several regions on mHtt (polyclonal) could also be envisioned. One such pre-clinical study has been conducted for the validation of an antibody targeting proteolytically-cleaved mHtt fragments. This antibody, designated C6-17 (AFFiRiS AG ), was designed to recognize and bind to mHtt fragments that have been cleaved by the caspase-6 enzyme (aa 586) (Bartl et al., 2019; Bartl et al., 2017; Smrzka et al., 2016) (Fig. 1) . In vitro assessment of this antibody has shown that C6-17 is not only very efficient in binding to free, extracellular forms of mHtt, but by doing so, can prevent cell-to cell spread of mHtt. In vivo target engagement of C6-17 resulted in a decrease of mHtt levels in plasma and liver of YAC128 mice administered this antibody (Bartl et al., 2019; Smrzka et al., 2016) .
Lessons learned from antibody-based therapy tested in other disease contexts
Pioneering work in Alzheimer's disease (AD) immunotherapy has resulted in the production and testing of a large number of antibodies. Despite the fact that this has culminated in an astonishing 33 failed trials, it has allowed the development of antibodies against other proteins associated to various other neurodegenerative disorders including PD, amyotrophic lateral sclerosis (ALS) and prion diseases. HD is a trinucleotide repeat proteinopathy which shares several features with other neurodegenerative disorders. Taking a critical look at immunotherapeutics conceptualized and tested for other neurodegenerative diseases will most certainly provide guidance in designing optimal antibody therapies for HD.
Table 2
Outcome of antibody-based therapies in pre-clinical models of HD -targeting extracellular mHtt.
Abbreviations: DNA, deoxyribonucleic acid; cDNA, complementary deoxyribonucleic acid; Httex1-Qn, huntingtin exon 1 with 'n' glutamine repeats; mHtt, mutant huntingtin; WT, wild type.
Lessons from neurodegenerative disorders
Immunotherapies for AD have mainly been aimed at attenuating the innate pro-inflammatory immune response, or facilitating the clearance of Aβ (St-Amour et al., 2016) . The very first trial using active immunization began in 2000, with phase I and IIa trials yielding mixed results. Despite the fact that only a few of the patients treated with AN-1792 (roughly 50%) mounted a significant antibody response (Lee et al., 2005b) and that there were no measurable cognitive improvements (Holmes et al., 2008; Nicoll et al., 2003) , post-mortem evaluation revealed that patients had markedly less amyloid plaques (Boche et al., 2010) . Testing of patient CSF showed a trend toward a decrease in phosphorylated tau concentrations and post-mortem analysis indicated a reduction of aggregated tau in neuronal processes (Boche et al., 2010) . However, 6% of the treated AD participants also had marked T lymphocyte infiltration and inflammation around leptomeningeal blood vessels, especially near vascular amyloid deposits leading to aseptic meningoencephalitis, which was fatal in some cases (Nicoll et al., 2003; Orgogozo et al., 2003) . The T lymphocyte infiltration seen in AD patients in response to this vaccine has been attributed to an overexpression of transforming growth factor -beta isoform 1 (TGF-β1) following administration of Aβ 1-42 peptide (Buckwalter et al., 2006) . As a result of this and other unsuccessful trials, a second-generation of vaccines emerged with the goal to prompt a significant antibody production without engaging T lymphocytes, previously shown to participate to the harmful host response following immunization. A range of new strategies are being exploited to produce Aβ antibodies that would not generate undesired immune responses from the host based on the use of modified antigens (Davtyan et al., 2013; Liu et al., 2013; Guan et al., 2012; Mantile et al., 2011; Bach et al., 2009) . For example, the Aβ peptide could be coupled to virus-like particles (Mantile et al., 2011; Bach et al., 2009) , glycine/proline spacer sequence (GPGPG) (Guan et al., 2012) or a foreign epitope such as the diphtheria toxin (Davtyan et al., 2013; Liu et al., 2013) to improve the generation of therapeutic antibodies.
Preclinical studies testing passive immunization have demonstrated the ability to decrease amyloid pathology in AD mouse models, with some reports of improvements in cognitive functions (Dai et al., 2017; Cattepoel et al., 2011; Lee et al., 2006; Levites et al., 2006; Wilcock et al., 2004) . However, passive immunization has also been associated with adverse effects in animal models of AD as well as in patients. For example, cerebral micro-haemorrhages and meningoencephalitis were reported in some mice models (Li et al., 2012; Petrushina et al., 2008; Wilcock et al., 2007; Wilcock et al., 2004; Lee et al., 2005a Lee et al., , 2005b . Clinical trials with the anti-Aβ monoclonal antibody bapineuzumab induced vasogenic edema and a range of undesirable adverse events including deep vein thrombosis, hypertension, anxiety and paranoia which prompted early termination of the trial (Salloway et al., 2014) . One possible explanation for the number of antibody failures may relate to the targeted forms of Aβ that may not be key players in the underlying AD-pathology. Building on these trials, a new wave of passive immunotherapies is seeking to target specific Aβ species such as oligomers (crenezumab) (Yang et al., 2019) , protofibrils (BAN2401 and SAR228810) (Pradier et al., 2018; Logovinsky et al., 2016) and insoluble fibrils (BIIB037) (Goure et al., 2014) , rather than Aβ monomers. For example, the class of antibody referred to as AZ59, and which has been designed to block the interaction of cellular prion protein (PrPc) and Aβ oligomers, can rescue memory deficits in manifest APP/PS1 mice (Cox et al., 2019) . The relevant take home messages from these AD trials include: 1) selecting the right epitope targets to lessen the neuropathological burden, i.e. the targeting of soluble Aβ oligomers instead of insoluble forms and 2) avoiding deleterious engagement of the immune system and rather harness its more beneficial properties.
Despite the fact that there are fewer immunotherapeutics for PD, those that exist have shown to generate higher success rate preclinically. The main pathology in PD is the presence of intracellular agglomerations of α-Syn known as Lewy bodies or Lewy neurites (Spillantini et al., 1998) . The observation of Lewy body pathology within foetal neuronal grafts in PD patients (Kordower et al., 2008; Li et al., 2008) lead to the idea that α-Syn could spread between cellular elements. Both in vitro and in vivo studies have shown that α-Syn can be released into the extracellular matrix where it aggregates, is taken up by neighbouring cells and effectively seeds pathology (see review (Vargas et al., 2019) ). Pioneering pre-clinical work demonstrated that intra-striatal inoculation of synthetic α-Syn fibrils in WT mice could spread between cells leading to the appearance of Lewy body structures in the substantia nigra pars compacta, the primary brain region targeted in PD. This resulted in the loss of dopaminergic neurons and subsequent motor deficits (Luk et al., 2012a) . Intracerebral administration of brain homogenates derived from symptomatic, transgenic mice overexpressing human A53T mutant α-Syn (M83 +/+ ), or injection of synthetic preformed α-Syn fibrils, was further reported to accelerate the formation of α-Syn aggregates and precipitate neurological dysfunction in asymptomatic M83 +/+ mice (Luk et al., 2012b) . It is therefore imperative, given the resemblance of the prion-like properties of α-Syn and mHtt, to look the outcomes of PD immunotherapies when designing new strategies for HD.
Development of antibodies that specifically bind to the aggregated form of α-Syn, such as PRX002, have recently been reported to be safe and well-tolerated (Schenk et al., 2017) although improvement on clinical measures were not significant (Jankovic et al., 2018) . Results also showed that unbound serum α-Syn was reduced by up to 97%, indicating robust peripheral target engagement. Another immunotherapeutic under trial and showing promise is the Affitope PD01A by AFFiRiS AG ("AFFITOPE® PD01A, 2016) . This vaccine is designed to trigger an immune reaction against α-Syn and has already cleared safety and tolerability. After 26 weeks of treatment, the results further unveiled a trend towards lower levels of oligomeric α-Syn both in the blood and CSF of treated patients. The success of these antibodies adds further weight to the concept that therapeutics aimed at binding free extracellular proteins to prevent cell-to-cell spread of pathogenic proteins are a tractable and viable target for HD as well. Another exciting new therapeutic avenue is based on a recent study testing the scFv antibody, VH7VK9, confirmed to bind the RNA recognition motif 1 (RRM1) of the TAR DNA binding protein-43 (TDP-43) in ALS. Administration of these antibodies reduced microgliosis in the scAAV2/9 TDP-43 mouse model and improved cognitive as well as motor deficits (Pozzi et al., 2019) .
Lessons from prion disorders
Along with conventional antibodies, intrabodies and secreted intrabodies have been employed to stabilize native state proteins, inhibit the oligomerization or fibril formation process, neutralize toxic oligomeric protein forms and promote clearance of preformed aggregates in prion diseases (Aguzzi et al., 2018) . Active immunization with a small prion fragment designed to fit into the major histocompatibility complex class II binding pockets has been shown to induce the production of anti-PrPc antibodies leading to the reduction of proteinase K resistant PrPc levels in prion-infected mice (Souan et al., 2001) . In another study, BALB/C mice were immunized with recombinant succinyl arginine dihydrolase (SADH), a bacterial enzyme that carries aa sequences similar to prion epitopes. In response to immunization, mice produced antibodies that were able to recognize and bind prion proteins (PrP), consequently displaying prolonged survival compared to their non-immunized counterparts (Rosset et al., 2009) . In another study, CD-1 mice were orally administered with an attenuated bacterial vector (LVR01) expressing mouse PrP and allowed to develop an immune response. Mice were subsequently administered the scrapie prion protein (PrPsc) isoform 139A. The results revealed that mice with high titre of antibodies remained symptom free 13 months following treatment (Goñi et al., 2008) . Passive immunization has also been reported to result in some degree of success in tackling prion disease. Transgenic expression of the μ heavy chain variable fragment of the PrPc-specific monoclonal antibody 6H4 in PrP heterozygous mice completely prevented prion infection when the PrPsc was delivered intraperitoneally (Heppner et al., 2001) . Antibodies developed to tackle prion diseases are extremely relevant to understanding and designing antibodies for HD since both conditions are characterized by misfolded proteins that cause dysfunction, spreading and seeding of pathology.
Crossing the blood-brain-barrier
Targeting the CNS with immunotherapies will further need to overcome important obstacles foremost is the inherent difficulty of developing safe, yet efficient antibodies that can cross the blood-brainbarrier (BBB). In addition to the BBB, the blood-cerebrospinal fluid barrier, blood-retinal and blood spinal-cord barriers all limit the transit of substances from the periphery to the CNS (Neuwelt et al., 2011) . Preclinical studies have shown that antibodies do cross the BBB, but only in small amounts with as few as 0.1-0.2% of circulating antibodies entering the brain (Yu and Watts, 2013) . Another consideration is that the BBB is compromised in several neurodegenerative disorders (Sciacca and Cicchetti, 2017; Drouin-Ouellet et al., 2015; Friese et al., 2014; Ham et al., 2014; Kwan et al., 2012a; van Assema et al., 2012; Mosconi et al., 2008) . Consequently, the entry of antibodies to the brain may be easier than in the non-diseased adult CNS. A viable solution to improve transport of antibodies into the CNS could lie in augmenting or facilitating transport of antibodies across the BBB without altering the BBB itself. One such approach could be through using some form of receptor-mediated transport (Pulgar, 2018) . More recent technology design such as microbubble-facilitated focused ultrasound (FUS) (Hsu et al., 2013) combined with magnetic resonance imaging (MRI)-Guided Focused Ultrasound for Targeted Delivery of Recombinant AAV, shows promise to enhance/facilitate therapeutic gene delivery into the brain (Noroozian et al., 2019) .
Bioinformatics: an additional tool to assist in antibody development
In addition to probing other brain disorders for optimal antibody design, novel screening methods and data driven drug discovery approaches also offer a means by which to engineer future antibodies or to repurpose existing ones. ProMIS Neurosciences Inc. -a biotechnology company focusing on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disorders -has employed a proprietary discovery platform to generate several antibody candidates for PD (ProMIS Neurosciences, 2019) . These antibodies are thought to directly target the toxic forms of α-Syn. ProMIS antibody candidates have demonstrated a high degree of selectivity for only the toxic forms of α-Syn in a side-by-side comparison with other α-Syn targeting antibodies that are currently in development. Similarly, stimulation studies have already charted the method by which homogeneous Httex1 oligomers are formed (Chen and Wolynes, 2017; Chen et al., 2016) , laying the foundation for computer-driven analysis of the Htt/mHtt protein. One such example is a recent combined in vitro and in silico study in which cells transfected with normal and pathological forms of the protein and computational methods were used to determine the regions in the exon 1 of mHtt that are crucial for binding normal Htt (Bonfanti et al., 2019) . The regions of interest reported in this particular study could be used as a roadmap to design novel antibodies that would destabilize pathogenic oligomers of mHtt.
One of the fastest growing areas of the 'antibody as therapeutics' industry is the discovery and screening platforms for immunoglobulins. Biopharmaceutical companies have recognized the need for high throughput platforms, a rapid process for therapeutic antibodies to be discovered and screened. The advantages of such platforms are their ability to not only expedite antibody discovery but also find the most appropriate immunotherapeutic for a pathogenic protein such as mHtt. For instance, platforms using surface display methods are capable of recapitulating the key steps taking place in vitro or in vivo (Parola et al., 2018) . This technique has proven very useful, as demonstrated by the approval of Humira® adalimumab for the treatment of arthritis, the first platform generated antibody-based therapeutic to enter the market. Another advantage of using this new method is the ability to infer antigen specificity by combining large-scale sequencing data and bioinformatics. This provides advantages over standard single-cell or hybridomas by a) allowing for the identification of antibodies with improved biophysical characteristics (binding affinity, stability) while b) avoiding laborious and costly laboratory procedures as antibodies are identified in silico (Georgiou et al., 2014) . One such example is the DeepDisplay™ platform offered by ImmunoPrecise (ImmuenoPrecise Antibodies LTD, 2019). The DeepDisplay™ platform has been conceptualized to discover therapeutic antibodies using a combination of transgenic animal immunizations and custom phage display antibody selection, eliminating a considerable number of animal experiments as well as the time required to screen antibodies. Other platforms, such as Nebula™ from ImmuneBiosolutions ("Nebula Antibody Platform -Immune Biosolutions, 2018) and Evotec ("Antibody platform -Evotec, 2019) should be exploited to speedup antibody discovery and production, especially for challenging antigens, such as those to target mHtt. The future of HD immunotherapy may need to involve sophisticated bioinformatic platforms to achieve the best possible outcomes. Such approaches could not only significantly reduce the time taken for an antibody to come to market, but also allow for the repurposing of existing antibodies with the potential to work in HD.
Combining immunotherapy with RNA/DNA modifying approaches: the ideal way forward
mHtt-related alterations in chromatin modulation and transcriptional/translational dysfunction have been suspected to play a role in HD pathogenesis (Thomas et al., 2008; Ryu et al., 2006) making drugs that seek to tackle these aspects of great interest. In this context, an ideal combination therapeutic will be composed of medications capable of reducing the production of the mutant protein, while simultaneously eliminating the residual deleterious proteins. The pairing of immunotherapies with DNA/RNA modulating approaches could therefore provide a more complete depletion of mHtt (Fig. 2) . The most successful RNA modifying therapies are the ASO (RG6042, IONIS-HTTRx) (Tabrizi et al., 2019) or miRNA-based compounds (AMT-130, by uniQuer and VY-HTT01 by Voyager therapeutics) (Inacio, 2019; Melão, 2018) . DNA modifying therapies using CRISPR/Cas9 gene editing system have also been shown to decrease mHtt levels in HD140Q-KI mice resulting in reduced astrogliosis and improved motor performance (Yang et al., 2017) . However, these methods, by themselves, cannot completely eradicate mHtt, which leaves a quantity of intracellular and extracellular mHtt still capable of inducing pathology. HD carriers live for decades with elevated mHtt levels without developing the disease, raising the question as to whether decreasing the amounts of mHtt could be sufficient to generate measurable improvements. While reducing intracellular mHtt is clearly important, the extracellular mHtt should not be ignored as a depletion of intracellular protein does not abrogate the presence or build up of its extracellular counterpart. Any efforts to reduce intracellular mHtt, if done while not clearing the extracellular mHtt, would be suboptimal given that the protein could reenter into, and infect other cells. DNA/RNA modifiers combined with immunotherapies would maximize mHtt reduction, both intracellularly and extracellularly. Another possible concern that these therapies and some antibodies share is the extent to which they impact Htt while efficiently reducing mHtt. Knocking out Htt during development is lethal to mice embryos (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995) . The role of Htt in adults, however, is less well understood.
Htt has been described to play several important roles such as in adult neurogenesis, synaptic function, stress-response and DNA damage repair and macro-autophagy (Maiuri et al., 2017; Rui et al., 2015; McKinstry et al., 2014; Godin et al., 2010; Rigamonti et al., 2000) . Ongoing trials with ASOs will be critical to understand the impact of reducing Htt in adult subjects.
Concluding remarks
Targeting mHtt using antibodies offers several advantages: 1) immunotherapy can be based on two different mechanisms of action i.e. (passive) and host-produced (active) approaches, 2) they offer ease of target engagement; 3) they can be designed to reduce mHtt, 4) there is flexibility in antibody design, 5) they have the ability to effectively modulate pathogenic proteins without having to modifying the gene or RNA that produces it, both more complicated procedures. This concern is highly relevant as gene therapies currently being tested in the clinic are not allele specific. Finally, 6) antibodies are administered by easier delivery routes than intra-thecal injections, for example. As for any other fields, designing and developing novel therapeutics, such as antibodies, should aim to create a successful therapeutic that can treat a large number of patients, be straightforward to administer, comparatively cost-effective and have as few side-effects as possible. Based on the evidence, all of this may be feasible for treating HD using an antibody approach.
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Fig. 2.
Potential of combination therapies to target both intracellular and extracellular mHtt. mHtt can be targeted both intracellularly and extracellularly at the gene, mRNA and protein level. Ideally, novel therapeutic approaches would combine more than one of these modalities to reduce mutant protein content. Abbreviations: CRISPR, clustered regularly interspaced short palindromic repeats; CAS9, CRISPR associated protein 9; DNA, deoxyribonucleic acid; mHtt, mutant huntingtin; mRNA, messenger ribonucleic acid; RNA, ribonucleic acid.
